Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…ation and highlight that further investigation into the optimal UDCA dosing strategy is warranted.Abstract IDDF2026-ABS-0146 Figure …
… was recently withdrawn from the US creating a therapeutic gap. Seladelpar (SEL), approved in 2024 in the US for patients with PBC and an …
…atment approach is a step-up model, wherein first-line therapy, ursodeoxycholic acid (UDCA), is given for a minimum of 12 months before the addition of sec…
…binding to its promoter. Pharmacological inhibition of FXR with UDCA reversed T-cell exhaustion, and synergized with anti-PD-L1 ther…
…dentified for the 2018–2021 period; 67 patients did not receive UDCA and were excluded from the sample. A total of 1689 patients wer…
…%) normalised within 6 months as compared to 18/28 (64.3%) with fenofibrate. This was not significantly different between the groups (p=0.4…
…Aim Ursodeoxycholic acid (UDCA) is the licensed 1st-line therapy for Primary Biliary Cholangiti…
…us reports that UDCA acts as a gut FXR antagonist. In addition, UDCA seems to be exerting liver protective effects predominantly in …